Emergent Drug Panel-Version 2 (EDP-V2) Kit
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, and distribution of the Emergent Drug Panel-Version 2 (EDP-V2) Kit. This initiative is part of the Traceable Opioid Material program and focuses on providing reference materials for emerging synthetic opioids and other novel psychoactive substances to approved laboratories. The anticipated period of performance runs from September 30, 2026, through September 29, 2027, with four additional option years for continued production and distribution. The selected contractor is responsible for ensuring all materials meet Current Good Manufacturing Practice standards and maintaining the necessary DEA registrations for the distribution of controlled substances. Key deliverables include providing technical support to recipient laboratories, conducting stability testing for shelf-life extensions on existing materials, and reporting distribution and use-case metrics to the CDC. This procurement is being conducted under the authority of FAR 12.102(a) to address the critical need for standardized reference materials in combating the opioid epidemic.
General Info
Agency
NAICS
Place of Performance
Atlanta, GA, 30341, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, distribution, and associated laboratory support services for the Emergent Drug Panel-Version 2 (EDP-V2) Kit, a new product line addition within CDC's Traceable Opioid Material (TOM®) Kit program, and continued distribution, product support, and data collection services for existing Emergent Drug Panel (EDP) Kit products. The anticipated period of performance is 09/30/2026 through 09/29/2027. The requirement will include four option years for design and manufacture of additional kits as well as continuous distribution. The Government intends to solicit and negotiate with only one source under the authority of FAR 12.102(a).
CDC requires a contractor to:
1. Design and manufacture EDP-V2 kits containing reference materials for emerging synthetic opioids and related drugs of concern (including synthetic opioids, novel benzodiazepines, synthetic cathinones, and related novel psychoactive substances) contributing to the opioid epidemic, meeting or exceeding Current Good Manufacturing Practice (cGMP) standards;
2. Obtain and maintain a DEA exemption/registration status enabling distribution of controlled and non-controlled reference materials to CDC-approved laboratories;
3. Distribute EDP-V2 kits and all other existing EDP Kit product lines to approved laboratories nationally;
4. Provide ongoing product support, customer service, and technical assistance to recipient laboratories for all EDP Kit products;
5. Collect, maintain, and report kit distribution and use-case metrics to CDC in accordance with OMB-approved data collection requirements; and
6. Conduct stability testing on existing EDP Kit materials nearing expiration to determine potential for shelf-life extension.
This notice of intent is not a request for competitive quotations; however, all quotations/responses received prior to the date and time below will be considered by the government. NOTE: Interested vendors must clearly provide evidence of their capability to be considered. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the Contracting Officer at xur0@cdc.gov by 11:00AM (ET) on 09/14/2026.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → CDC Office Of Acquisition Services
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
